Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ECONOMIC-EVALUATION OF PHARMACIST INVOLVEMENT IN DISEASE MANAGEMENT IN A COMMUNITY PHARMACY SETTING
Autore:
MUNROE WP; KUNZ K; DALMADYISRAEL C; POTTER L; SCHONFELD WH;
Indirizzi:
MEDOUTCOMES INC,POB 6813 RICHMOND VA 23298
Titolo Testata:
Clinical therapeutics
fascicolo: 1, volume: 19, anno: 1997,
pagine: 113 - 123
SICI:
0149-2918(1997)19:1<113:EOPIID>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Keywords:
DISEASE MANAGEMENT; PHARMACOECONOMICS; PHARMACEUTICAL CARE; COMMUNITY PHARMACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
W.P. Munroe et al., "ECONOMIC-EVALUATION OF PHARMACIST INVOLVEMENT IN DISEASE MANAGEMENT IN A COMMUNITY PHARMACY SETTING", Clinical therapeutics, 19(1), 1997, pp. 113-123

Abstract

This study evaluated the economic impact of patient-focused pharmacist intervention in the community retail setting in patients with hypertension, diabetes, asthma, and/or hypercholesterolemia. Specially trained pharmacists intervened by providing targeted patient education, performing systematic patient monitoring, offering feedback and behavior modification, and communicating regularly with patients' physicians toenable early intervention for drug-related problems. We evaluated prescription drug costs and total medical costs by comparing claims data from 188 patients enrolled in the program at three intervention pharmacies with data from 401 control patients at five nonparticipating pharmacies from the same retail chain. For all disease states, the averagecost per prescription was significantly higher in the group receivingintervention than in the control group. Differences in total monthly prescription costs were significant only for patients with asthma, with higher monthly costs in the group receiving intervention. Substantial savings were demonstrated across all cost analyses for total monthlymedical costs. Savings ranged from a conservative estimate of $143.95per patient per month to $293.39 per patient per month when accounting for the possible influence of age, comorbid conditions, and disease severity. Our data indicate that pharmacist intervention in this community pharmacy-based disease management model substantially reduced monthly health care costs in patients with hypertension, hypercholesterolemia, diabetes, and asthma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/05/20 alle ore 14:43:38